Clinical Trial Detail

NCT ID NCT03114527
Title Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Fox Chase Cancer Center
Indications

liposarcoma

leiomyosarcoma

Therapies

Everolimus + Ribociclib

Age Groups: adult senior

Additional content available in CKB BOOST